“Genmab’s Bright Future: Anticipating Johnson & Johnson’s Decision for 2025”
Genmab Reports Strong Q4 2024 Results Breaking Expectations and Showing Growth Genmab, a biotechnology company, recently announced their financial results for the fourth quarter of 2024, and the numbers are impressive. The company reported $897.4 million in revenue, beating expectations and showing a 29% year-over-year growth. This exceptional performance was largely driven by the royalties…